Repare Therapeutics secured a $267 million global licensing deal with Debiopharm for its cancer drug Lunresertib. The deal includes $10 million upfront and up to $257 million in milestones, with Debiopharm taking over development. Repare will focus on early-stage trials for other candidates. Retail sentiment turned 'extremely bullish'.